Ovid Therapeutics Inc.OVIDNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank27
3Y CAGR-4.7%
5Y CAGR-12.1%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-4.7%/yr
vs +1.9%/yr prior
5Y CAGR
-12.1%/yr
Recent acceleration
Acceleration
-6.6pp
Decelerating
Percentile
P27
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $49.39M | -20.9% |
| 2024 | $62.45M | +4.7% |
| 2023 | $59.67M | +4.6% |
| 2022 | $57.05M | -32.2% |
| 2021 | $84.17M | -10.5% |
| 2020 | $94.05M | +53.1% |
| 2019 | $61.41M | +16.0% |
| 2018 | $52.93M | -18.6% |
| 2017 | $65.01M | +188.5% |
| 2016 | $22.54M | - |